Halozyme and GSK Partner on Next-Gen ADC Cancer Therapies
SAN DIEGO, May 7, 2026 Halozyme Therapeutics, Inc. announced a major global collaboration and license agreement with GSK to...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SAN DIEGO, May 7, 2026 Halozyme Therapeutics, Inc. announced a major global collaboration and license agreement with GSK to...
SHANGHAI, China – May 8, 2026 Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that...
NORTH CHICAGO, Ill., May 5, 2026 AbbVie Inc. has presented extensive new data across its gastroenterology portfolio at the...
REYKJAVIK, Iceland, Feb. 5, 2026 —Alvotech announced positive top-line results from a pivotal pharmacokinetic (PK) study evaluating AVT80, its...
Phoenix, AZ | October 27, 2025 – Johnson & Johnson’s TREMFYA® (guselkumab) becomes the first and only IL-23 inhibitor...
Newark, Del., October 3, 2025 – Avobis Bio LLC, a clinical-stage biotechnology company focused on implantable cell therapies, announced...
HORSHAM, Pa., Sept. 19, 2025 — Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug...
